newsfilter
← Latest News
GlobeNewswire·

CERo Therapeutics Announces Activation of Additional Clinical Trial Site for the CERTAIN-T Trial, its Ongoing Phase 1 Clinical Trial of CER-1236 in Hematological Cancers

SOUTH SAN FRANCISCO, Calif, Oct. 26, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company advancing